IgA nephropathy: To treat or not to treat?

Nephron

Volumn 75, Issue 3, 1997, Pages 251-258

  Scheinman, Jon I ^a   Trachtman, Howard ^b   Lin, Ching Yuang ^c   Langman, Craig B ^d   Chan, James C M ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d CHILDREN'S MEMORIAL HOSPITAL   (United States)

Author keywords

Berger s disease; Glomerulonephritis; IgA nephropathy; Oxidant injury; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; CORDYCEPS SINENSIS EXTRACT; CORTICOSTEROID; CYCLOSPORIN; DANAZOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; FISH OIL; MEPREDNISONE; OXYGEN RADICAL; PHENYTOIN; PREDNISONE; SALICYLIC ACID; UROKINASE;

ARTICLE; DISEASE COURSE; HEMATURIA; HUMAN; HYPOTHESIS; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY FUNCTION; PATHOGENESIS; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; TREATMENT FAILURE; UPPER RESPIRATORY TRACT INFECTION;

EID: 0031039051     PISSN: 16608151     EISSN: 22353186     Source Type: Journal    
DOI: 10.1159/000189545     Document Type: Article

References (103)

1. D'Amico G: The commonest glomerulonephritis in the world. O J Med 1987:64:709-727.
2. D’Amico G. Imbasciati E. Barbiano DG. Ber-toli S, Fogazzi G, Ferrano FG, Ragni A, Cola-santi G, Minetti L: Idiopathic IgA mesangial nephropathy. Clinical and histological study of 374 patients. Medicine 1985:64:49-60.
3. Droz D. Kramar A. Noel LH, Nawar T: Primary IgA nephropathy: Prognostic factors. Con-trib Nephrol Basel. Karger. 1984, vol 40, pp 202-207.
4. Agodoa LYC: US Renal Data System. USRDS 1994 Annual Data Report. Bethesda, NIH N1DDK. 1994.
5. Donadio JV, Bergstralh MS. Offord KP. Spencer DC. Holly KC: A controlled trial offish oil in IgA nephropathy. N Engl J Med 1994:331: 1194-1199.
6. DeStrihou CVY: Fish oil for IgA nephropathy? N Engl J Med 1994;33:1227-1229.
7. Costa RS. Droz D. Noel LH: Longstanding spontaneous clinical remission and glomerular involvement in primary IgA nephropathy (Berger's disease). Am J Nephrol 1987;7:440-445.
8. Ibels LS. Gyory AZ: Long-term prognosis of IgA nephropathy. J Am Soc Nephrol 1993:4: 680.
9. Yoshikawa N. White RHR: IgA nephropathy; in Holliday M. Barratt TM. Avner ED (eds): Pediatric Nephrology. Baltimore. Williams & Wilkins, 1994. pp 719-728.
10. Rastofi S. Grande J, Sebo TJ: Increased glomerular proliferation index assessed by Ki-67 staining predicts an adverse course of IgA nephropathy (abstract). J Am Soc Nephrol 1993; 4:688.
11. Yokoyama H, Takaeda M. Wada T. Ogi M. Tomosugi N. Takabatake T. Abe T. Yoshimura M, Kida H, Kobayashi K: lntraglomcrular expression of MHC class II and Ki-67 antigens and serum y-interferon levels in IgA nephropathy. Nephron 1992;62:169-175.
12. McCormick D. Chong H. Hobbs C. Datta C. Hall PA: Detection of the Ki-67 antigen in fixed and wax-embedded sections with the monoclonal antibody MIBI. Histopathology 1993:22:355-360.
13. Welch TR. Fryer C. Shely E. Wolle DP, Quinlan M: Double-blind, controlled trial of shortterm prednisone therapy in immunoglobulin A glomerulonephritis. J Pediatr 1992:121:474-477.
14. Ohashi T, Shimokawahara H. Fukumoto A, Azunta K, Uchida Y. Tokuda Y. Ito H. Yasu-moto Y, Yamashita W. Harada R: Effects of steroid therapy in IgA nephropathy. Fukuoka IgakuZasshi 1992;83:209-215.
15. Julian BA. Barker CV. Woodford SY: Alternative-day prednisone treatment of patients with IgA nephropathy (abstract). J Am Soc Nephrol 1993:4:681.
16. Yoshimura M. Kida H. Saito Y. Talkaeda M. Sugioka G: Effects of méthylprednisolone pulse therapy on progressive IgA nephropathy. Nippon Jinzo Gakkai Shi 1991;33:761-768.
17. Lin CY: Treatment of IgA nephropathy. Springer Semin Immunopathol 1994:16:121-127.
18. Walker RG. Yu SH. Owen JE. Kincaid-Smith P: The treatment of mesangial IgA nephropathy with cyclophosphamide, dipyridamole and warfarin: A two-year prospective trial. Clin Nephrol 1990:34:103-107.
19. Orlowski T. Gorski A, Rancewicz Z, Mor-zycka-Michalik M. Smogorzcwski M. Maldyk M. Lao M, Szczesny-Nowicka B: IgA nephropathy: A long-term progressive study. Miner Electrolyte Metab 1990:16:54-56.
20. Lai KN, Lai FM. Li PK. Vallance-Owen J: Cyclosporin treatment of IgA nephropathy: A short-term controlled trial. Br Med J 1987:295: 1165-1168.
21. Woo KT. Edmonson RP. Yap HK, Wu AY. Chiang GS. Lee EJ. Pwee HS, Lim CH: Effects of triple therapy on the progression of mesangial proliferative glomerulonephritis. Clin Nephrol 1987;27:56-64.
22. Hotta O, Taguma Y, Kurosawa K. Sudo K, Suzuki K. Horigome L: Early intensive therapy for clinical remission of active IgA nephropathy: A three-year follow-up study. Nippon Jinzo Gakkai Shi 1993;35:967-973
23. Cattran DC: Current status of cyclosporine A in the treatment of membranous. IgA and membranoproliferalive glomerulonephritis. Clin Nephrol 1991;35:S43-S47.
24. Tomino Y, Sakai H. Miure M, Takao S. Endoh M. Nomoto Y: Effect of danazol on solubilization of immune deposits in patients with IgA nephropathy. Am J Kidney Dis 1984:4:135-140.
25. Black WD: Treatment of IgA nephropathy with danazol (abstract). J Am Soc Ncphr 1993:4: 674.
26. Nicholls K, Becker G. Walker R, Wright C, Kincaid-Smith P: Plasma exchange in progressive IgA nephropathy. J Clin Apheresis 1990:5: 128-132.
27. Lai KN. Lai FM, Leung ACT, Vallance-Owen J: Plasma exchange in patients with rapidly progressive idiopathic IgA nephropathy. Am J Kidney Dis 1987;10:66-70.
28. Okamura M. Kanayama Y. Negoro N. Inoue T, Takeda T: Long-term effects of calcium antagonists and angiotensin-converting enzyme inhibitors in patients with chronic renal failure of IgA nephropathy. Contrib Nephrol. Basel. Karger. 1991, vol 90. pp 161-165.
29. Ye RG: Treatment of IgA nephropathy by integrated traditional and Western medicine. Chung Kuo Chung Hsi I Chieh Ho Tsa Chih 1992;12:17-19.
30. Trachtman B. Schwob N: Administration of vitamin E attenuates chronic puromycin ami-nonuclcoside nephropathy. J Am Soc Nephrol 1994:5:1811-1819.
31. Murakami T. Kawakami H: Urokinase, a scavenger of affected tubules in acute worsening during macroscopic hematuria of IgA nephropathy? Nephron 1990:55:92-93.
32. Clarkson AR. Seymour AE, Woodroffc AJ, McKenzie PE. Chan Y-L. Wootton AM: Controlled trial of phenytoin therapy in IgA nephropathy. Clin Nephrol 1980; 13:215-218.
33. Haber A, Nagy J. Deak G, Suie T: Long-term phenytoin (Diphedan) therapy leading to IgA nephropathy. Orv Hetil 1992:133:1631-1635.
34. Clarkson AR. Woodrofte AJ, Bannister KM. Odum J: Therapy in IgA nephropathy. Contrib Nephrol. Basel. Karger. 1993. vol 104. pp 189-197.
35. Sato M. Takayama K, Kojima H. Koshikawa S: Sodium cromoglvcate therapy in IgA nephropathy: A preliminary' short-term trial. Am J Kidney Dis 1990:15:141-146.
36. Bazzi C. Sinico RA. Petrini C. Rizza V, Torpia R, Arrigo G, Ragni A. D’Amico G: Low doses of drugs able to alter intestinal mucosal permeability to food antigens β-aminosalicylic acid and sodium cromoglvcatel do not reduce proteinuria in patients with IgA nephropathy: A preliminary non-controllcd trial. Nephron 1992;61:192-195.
37. Koichi K. Yamaji S. Kimura T. Yosizawa T, Tujie H: A clinicopathological study of IgA nephropathy after tonsillectomy-with emphasis on renal histology and the timing of tonsillectomy. Nippon Jibiinkoka Gakkai Kaiho 1993:96:1264-1269.
38. Bene MC. Hurault dcLigny B. Kessler M. Foli-guet B. Faure GC: Tonsils in IgA nephropathy. Contrib Nephrol. Basel. Karger. 1993. vol 104. pp 153-161.
39. Donadio JV: Omega-3 polyunsaturated fatty acids: A potential new treatment of immune renal disease. Mayo Clin Proc 1991:66:1018-1028.
40. Keydani SN, Rasmussen R. Dinarello H. Schaefer EJ: Immunologic effects of national cholesterol education panel step-2 diets with and without fish-derived N-3 fatty acid enrichment. J Clin Invest 1993;92:105-113.
41. Pettcrsson EE. Rekola S. Berglund L. Sund-qvist KG, Angelin B. Diczfalusky U, Bjorkhem I. Bergstrom J: Treatment of IgA nephropathy with omega-3-poIyunsaturated fatty acids: A prospective, double-blind, randomized study. Clin Nephrol 1994;41:183-190.
42. Cheng LKP. Chan PCK. Chan KK: The effect of fish-oil dietary supplement on the progression of mesangial IgA glomerulonephritis. Nephrol Dial Transplant 1990:5:241-246.
43. Bennett WM. Walker RG. Kincaid-Smith P: Treatment of IgA nephropathy with eicosapcn-taenoic acid: A two-year prospective trial. Clin Nephrol 1989:31:128-131.
44. Scharschmidt LA, Gibbons NB. McGarry L, Berger P, Axelrod M, Janis R. Ko YH: Effects of dietary fish oil on renal insufficiency in rats with subtotal nephrectomy. Kidney lnt 1987: 32:700-709.
45. Hamazaki T, Tatcno S. Shishido H: Eicosapen-taenoic acid and IgA nephropathy. Lancet 1994;Vol i: 1017-1018.
46. Imai T, Hirata Y. Kanno K. Marumo F: Induction of nitric oxide synthase by cyclic AMP in rat vascular smooth muscle cells. J Clin Invest 1994;93:543-549.
47. Clarke JTR. Cullen-Dean G. Regelink E: Increased incidence of epistaxis in adolescents with hypercholesterolemia treated with fish oil. JPcdiatr 1990:116:139-141.
48. Couser WG: Pathogenesis of glomerulonephritis. Kidney lnt 1993:42:S19-S26.
49. Rifai A: Immunopathogencsis of experimental IgA nephropathy. Springer Semin Immunopa-thol 1994:16:81-95.
50. Doi T. Striker IJ, Quaifc C. Conti FG, Palmi-ter R. Behringer R. Brinstcr R. Striker GE: Progressive glomerulosclerosis develops in transgenic mice chronically expressing growth hormone and growth hormone-releasing factor but not in those expressing insulin-like growth factor-1. Am J Pathol 1988;131:393-403.
51. Abboud HE: Growth factors in glomerulonephritis. Kidney lnt 1993:43:252-267.
52. Striker I J. Doi T. Elliot S: The contribution of glomerular mesangial cells to progressive glomerulosclerosis. Semin Nephrol 1989:9:318-328.
53. Flocge J. Johnson RJ. Gordon K. lida H. Pritzl P. Yoshimura A. Campbell C. Alpers CE. Couser WG: Increased synthesis of extracellular matrix in mesangial proliferative nephritis. Kidney lnt 1991;40:477-488.
54. Lajara R. Rotwein P. Bortz JD. Hansen VA. Sadow JL, Betts CR. Rogers SA. Hammerman MR: Dual regulation of insulin-like growth factor I expression during renal hypertrophy. Am J Physiol 1989;257:F252-F261.
55. Nakamura T, Ebihara L. Fukui M. Osada S. Nagaoka L. Horikoshi S. Tomino Y. Koide H: Messenger RNA expression for growth factors in glomeruli from focal glomerular sclerosis. Clin Immunol Immunopalhol 1993:66:33-42.
56. Alpers CE. Seifert RA. Hudkins KL. Johnson RJ. Bowcn-Pope DF: PDGF receptors localizes to mesangial, parietal epithelial, and interstitial cells in human and primate kidneys. Kidney lnt 1993:43:286-294.
57. Floege J. Bums MW. Alpers CE. Yoshimura A. Pritzl P. Gordon K. Seifert RA, Bowen-Pope DF, Couser WG. Johnson RJ: Glomerular cell proliferation and PDGF expression precede glomerulosclerosis in the remnant kidney model. Kidney lnt 1992:41:297-309.
58. Grande J. Melder D. Zinsmcister A. Killen P: Transforming growth factor-ßi induces collagen IV gene expression in NIH-3T3 cells. Lab Invest 1993:69:387-395.
59. Ziyadeh FN. Sharma K. Ericksen M. Wolf G: Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth lactor-ß. J Clin Invest 1994;93:536-542.
60. Yamamoto T. Noble NA, Miller DE, Border WA: Sustained expression of TGF-ßi underlies development of progressive kidney fibrosis. Kidney lnt 1994;45:916-927.
61. Shah SV: Light emission by isolated rat glomeruli in response to phorbol myristatc acetate. J Lab Clin Med 1981:98:46-57.
62. Pallar MS. Holdal JR. Ferris TF: Oxygen free radicals in ischemic acute renal failure in the rat. J Clin Invest 1984:74:1156-1164.
63. Johnson KJ, Rehan A, Ward PA: The role of oxygen radicals in kidney disease, in oxygen radicals and tissue injury. Proceeding of an Upjohn Symposium. 1987. pp 115-121.
64. Rehan A. Johnson KJ. Wiggins RC. Kunkel RG. Ward PA: Evidence for the role of oxygen radicals in acute nephrotoxic nephritis. Lab Invest 1984:51:396-403.
65. Sehrier RW. Harris DC. Chan L. Shapiro JI, Caramelo C: Tubular hypermetabolism as a factor in the progression of chronic renal failure. Am J Kidney Dis 1988; 12:243-249.
66. Ichikawa I. Kiyama S. Yoshioka T: Renal antioxidant enzymes: Their regulation and function. Kidney Int 1994:45:1-9.
67. Andreoli S: Reactive oxygen molecules, oxidant injury and renal disease. Pediatr Nephrol 1991;5:733-742.
68. Strattta P. Canavcsc C. Dogliani M. Mazzucco G. Monga G, Vercellone A: The role office radicals in the progression of renal disease. Am J Kidney Dis 1991:17:33-37.
69. Morrison AR. Portilla D: Lipid peroxidation and Ihe kidney; in Chow CK (ed): Cellular Antioxidant Defense Mechanisms. Boca Raton, CRC Press. 1988. pp 173-184.
70. Shah S: Role of reactive oxygen metabolites in experimental glomerular disease. Kidney lnt 1989:35:1093-1106.
71. Thakur V, Walker PD, Shah SV: Evidence suggesting a role for hydroxyl radical in puromycin aminonucleoside-induccd proteinuria. Kidney lnt 1988:34:494-499.
72. Baud L. Ardaillou R: Reactive oxygen species: Production and role in the kidney. Am J Physiol 1986:25:F765-F776.
73. Azzi A. Boscoboinik D. Chatelain E. Ozer NK. Strauble B: rJ-Alpha-tocopherol control of cell proliferation. Mol Aspects Med 1993:14:265-271.
74. Visscrs MCM. Winterboum CC: Oxidative damage to fibronectin. Arch Biochem 1991:15: 53-59.
75. Coppo R. Amore A. Gianoglio B, Cacace G. Picciotto G. Roccatello D. Pcruzzi L. Piccoli G, De Filippi PG: Angiotensin II local hyperreactivity in the progression of IgA nephropathy. Am J Kidney Dis 1993:21:593-602.
76. Russell MW. Mestccky J, Julian BA. Galla JH: IgA-associated renal diseases: Antibodies to environmental antigens in sera and deposition of immunoglobulins and antigens in glomeruli. J Clin Immunol 1986:6:74-86.
77. Owada A. Tomita K, Terada Y. Sakamoto H. Nonoguchi H, Marumo F: Endothelin (ET)-3 stimulates cyclic guanosine 3'5'-monophos-phate production via ETp receptor by producing nitric oxide in isolated rat glomerulus, and in cultured rat mesangial cells. J Clin Invest 1994:93:556-563.
78. Gerdes J. Lenike H, Baisch H. Wacker HH. Schwarting R, Stein H: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984;133:1710-1715.
79. Gerdes J. Schwab U. Lemke H. Stein H: Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983:31:13-20.
80. Cattoretti G. Becker MH. Key G. Duchrow M, Sehluter C, Galle J. Gerdes J: Monoclonal antibodies against recombinant parts of the Ki-67 antigen (M1B 1 and MIG 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992:168:357-363.
81. Harris CDH. Chan L. Schrier RW: Remnant kidney hypermetabolism and progression of chronic renal failure. Am J Physiol 1990:268: F1354-F1362.
82. Nath KA. Croatt AJ. Hostetler TH: Oxygen consumption and oxidant stress in surviving nephrons. Am J Physiol 1990;268:F1354-F1362.
83. Chen A, Chen WP. Shcn LF. Lin CY: Pathogenesis of IgA nephropathy: In-vitro activation of human mesangial cells by IgA immunocom-plex. J Pathol 1994:173:119-126.
84. Kashem A. Hndoh M. Nomoto Y. Sakai H. Nakazawa H: FcaR expression on polymorphonuclear leukocyte and Superoxide generation in IgA nephropathy. Kidney Int 1994:45: 868-875.
85. Bendich A, Machlin U: Safety of oral intake of vitamin E; in Packer L, Fuchs J (eds): Vitamin E in Health and Diseases. New York. Dekker. 1993. pp 411-416.
86. Murphy SP, Subar AMF, Block G: Vitamin E intakes and sources in the United States. Am J Clin Nutr 1990:52:161-167.
87. Boscoboinik D, Szcwczyk A, Hensey C, Azzi A: Inhibition of cell proliferation by alpha-tocopherol. Role of protein kinase C. J Biol Chem 1991:266:6188-6194.
88. Boscoboinik D. Chatelain E, Bartoli GM, Azzi A: Molecular basis of alpha-tocopherol inhibition of smooth muscle cell proliferation in vitro. EXS 1992:62:164-177.
89. Das SK. Fanburg BL: TGF-beta-l produces a ‘prooxidant’ effect on bovine pulmonary artery endothelial cells in culture. Am J Physiol 1991:26:L249-L254.
90. Goldring CE. Ricc-Evans CA, Arnold RH, Rao R, Hal L. Diploch AT: Alpha-tocopherol uptake and its influence on cell proliferation and lipid peroxidation in transformed and nontrans-formed baby hamster kidney cells. Arch Bio-chem Biophys 1993:303:429-435.
91. Spielberg SP. Boxer A, Corash LM. Schulman JD: improved erythrocyte survival with high-dose vitamin E in G6PD glutathione synthes-tase deficiencies. Ann Intern Med 1979:90:53-54.
92. Ehrenkranz RA. Bonta BW, Ablow RC. War-saaw JB: Amelioration of bronchopulmonary dysplasia after vitamin E administration. N Engl J Med 1978;299:564-569.
93. Macklin U: Vitamin E: A Comprehensive Treatise. New' York. Dekker, 1980, p 641.
94. Paul JL, Man NK, Moati N. Raichvang D: Membrane phospholopid peroxidation in renal insufficiency and chronic hemodialysis. Nephrologie 1991:12:4-7.
95. Costagliola C. luliano G. Menzione M. Simo-nelli F. Tortori A. Masturzi B, di Benedetto A. Rinaldi E: Systemic human diseases as oxidative risk factors in cataractogcncsis. 11. Chronic renal failure. Exp Eye Res 1990:51:631-635.
96. Nathan KA, Paller MS: Dietary deficiency of antioxidants exacerbates ischemic injury in the rat. Kidney Int 1990:38:1109-1117.
97. Nath KA. Salahudecn AK: Induction of renal growth and injury in the intact rat kidney by dietary deficiency of antioxidants. J Clin Invest 1990:86:1179-1192.
98. Thomas CE. Reed DJ: Radical-induced inactivation of kidney Na+, K(+)-ATPase: Sensitivity to membrane lipid peroxidation and the protective effect of vitamin E. Arch Bio-chem Biophys 1990;281:96-105.
99. Trachtman H. Del Pizzo R, Futtcrweit S. Levine D, Rao PS. Valdcrrama E. Sturman JA: Taurine attenuates renal disease in chronic puromycin aminonucleoside nephropathy. Am J Physiol 1992;262:F117-F123.
100. Gesualdo L. Emancipator SN. Kesselheim C. Lamm ME: Glomerular hemodynamics and eicosanoid synthesis in a rat model of IgA nephropathy. Kidney Int 1992:42:106-114.
101. Trachtman H. Chan JCM. Chan W. Brandt R, Wakely P. Futterweit S, Maesaka J. Ma C: Vitamin E ameliorates renal injury in an experimental model of IgA nephropathy. Pe-diatr Res 1996:40:620-626.
102. Fauck MC. Ng G. Zhang GY. Fanning GC. Roy LP. Bannister KM. Thomas AC. Clarkson AR. Woodroffe AJ. Knight JF: Infiltration of the kidney by αβγβ T cells: Effect on progression in IgA nephropathy. Kidney Int 1995:47:177-185.
103. Yi ZW. Rodriguez GE. Kneg RJ Jr, Tokieda K. Chan JCM: Brief communication: Rat macrophages in experimental IgA nephropathy. Biochem Molcc Med 1996:57:152-155.